Clinical Efficacy of Crizotinib as the First-Line Therapy of Advanced Non-Small-Cell Lung Carcinoma with ROS-1 Rearrangement: A Systematic Review
Background: Crizotinib is a drug designed to treat advanced NSCLC with ROS-1 rearrangement. Nevertheless, no reviews have assessed available studies to determine the efficacy and safety of first-line crizotinib against advanced NSCLC with ROS-1 rearrangement. Methods: PubMed, Cochrane Library, EB...
সংরক্ষণ করুন:
| প্রধান লেখক: | , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Dharmais Cancer Hospital - National Cancer Center
2023-06-01
|
| মালা: | Indonesian Journal of Cancer |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/933 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|